NEW YORK (GenomeWeb) – Paradigm today announced a collaboration with Deciphera Pharmaceuticals to predict best responders for Deciphera's kinase inhibitor called altiratinib. 

Paradigm will use its PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib in order to determine which patients may be sensitive or resistant to the MET, TIE2, VEGFR2, and TRK (A,B,C) kinase inhibitor. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.